Drugs Made In America Acquisition Corp. (DMAA) Form 10-Q — Aug 14, 2026
Drugs Made In America Acquisition Corp., a Nasdaq-listed blank check company, disclosed substantial doubt about its ability to continue as a going concern in its Q2 2026 10-Q, holding just $20,280 in cash outside its trust account against a $2.88 million working capital deficit. The SPAC's survival path runs through its definitive merger agreement with PAGC (Power Analytics Global Corporation), an AI, machine learning and cybersecurity technology platform, signed April 29, 2026 and already amended three times, most recently on July 14, 2026.
Key figures
- Eps
- 0.11
- Net Income
- 3697356
- Cash Position
- 20280
- Shares Outstanding
- 24276913
- Six month eps
- 0.11
- Q2 g and a costs
- 136934
- Total liabilities
- 9136624
- Ipo gross proceeds
- 200000000
- Q2 2025 net income
- 2288579
- Q2 2026 net income
- 1726897
- Redemption payout usd
- 99311220
- Six month g and a costs
- 280235
- Working capital deficit
- 2875440
- Interim note outstanding
- 350000
- Redeemable public shares
- 13559770
- Share redemptions payable
- 1661224
- Redemption value per share
- 10.71
- Shares redeemed april 2026
- 9440230
- Investor financing commitment
- 500000
- Over allotment gross proceeds
- 30000000
- Six month interest earned trust
- 3977591
- Deferred underwriting fee payable
- 6192000
- Extension deposits through june 30
- 600000
- Trust account balance june 30 2026
- 146834251
- Extension advance notes balance june 30
- 600000
- Extension advance notes balance post july 27
- 900000
Price after filing
Close on the filing date to close N calendar days later (from $10.71). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.